SOPHiA GENETICS, which provides a data-driven SaaS platform for the healthcare industry, raised $234 million by offering 13 million shares at $18, within the range of $17 to $19.
SOPHiA GENETICS provides a cloud-based software-as-a-service (SaaS) platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. In 2014, the company launched the first application of its platform to analyze NGS data for cancer diagnosis. As of March 31, 2021, it had approximately 240 applications used by healthcare providers, clinical and life sciences research laboratories and biopharmaceutical companies for precision medicine across oncology, rare diseases, infectious diseases, cardiology, neurology, metabolism and other disease areas.
SOPHiA GENETICS plans to list on the Nasdaq under the symbol SOPH. J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse acted as joint bookrunners on the deal.
